CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

CRISPR Therapeutics (CRSP) is positioned as the safer investment over Beam Therapeutics (BEAM), primarily due to its market-approved CRISPR/Cas9 therapy, Casgevy, which generated $30.4 million in Q2 2025 sales and is gaining momentum. CRSP shares have risen 36% year-to-date, supported by a broad pipeline including promising in vivo candidates and a strong $1.7 billion cash balance. Conversely, BEAM, a clinical-stage company utilizing base-editing technology, lacks an approved product, with its shares down 32% year-to-date, despite early promise for BEAM-101 in sickle cell disease and strategic partnerships. The article concludes that CRSP's commercialized product and financial strength provide a distinct advantage, making it the preferred choice despite its higher valuation.

Analysis

The gene-editing sector presents a clear divergence between commercial execution and clinical potential, as exemplified by CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM). CRSP has established a significant first-mover advantage with the multi-national approval of Casgevy, its CRISPR/Cas9 therapy for sickle cell disease and beta thalassemia. Commercial traction is accelerating, with product revenues doubling quarter-over-quarter from $14.2 million to $30.4 million and patient starts expected to grow significantly. This progress is underscored by a strong stock performance, up 36% year-to-date, and a robust financial position with $1.7 billion in cash. Furthermore, CRSP is de-risking its platform technology by advancing its pipeline, notably with encouraging early-stage data from its in-vivo candidate, CTX310. Conversely, BEAM remains a clinical-stage entity, with its prospects tied to its proprietary base-editing technology and lead candidate, BEAM-101. Despite promising initial data, the lack of an approved product and reliance on collaboration revenue create significant uncertainty, reflected in the stock's 32% year-to-date decline and widening loss estimates. While BEAM trades at a lower valuation (1.63 P/B vs. CRSP's 2.70 P/B), the market is clearly assigning a substantial premium to CRSP for its demonstrated commercial capabilities and reduced binary risk profile.

Key Decisions for Investors

• For investors prioritizing commercial execution and a de-risked profile, CRISPR Therapeutics (CRSP) warrants consideration, as its accelerating Casgevy sales and broad pipeline help justify its premium valuation.
• Investors with a higher risk tolerance and longer time horizon could view Beam Therapeutics' (BEAM) 32% year-to-date decline as a potential entry point, but this thesis is highly contingent on positive clinical data updates for its lead asset BEAM-101 later this year.
• Monitor CRSP's quarterly Casgevy revenue growth and patient uptake metrics, as sustained momentum is critical to validating the commercial model and supporting its current share price.
• Be aware that while CRSP's 2025 sales are projected to grow, its losses are expected to widen by 47%, indicating significant ongoing R&D and commercialization spend that will weigh on near-term profitability.